
Biogen collaborator NeuroSense shares secondary PhIIb data for its ALS treatment
NeuroSense announced secondary endpoint data for its ALS treatment, which is a combination of the antibiotic ciprofloxacin and the NSAID celecoxib. In the Phase IIb PARADIGM study, 68 patients received either NeuroSense’s treatment or placebo. […]